Screening MRI for Cancer Recurrence in Patients Treated With Breast Conserving Therapy

Sponsor
Seoul National University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01257152
Collaborator
(none)
754
1
61
12.4

Study Details

Study Description

Brief Summary

A prospective, multicenter study:
  • Primary objective: to assess the diagnostic yield of screening MRI compared to physical examination, mammography or ultrasonography in the detection of recurrence in patients treated with breast conserving therapy

  • Secondary objective: to describe the size, type, grade, and nodal status of cancers seen only on MRI and to estimate the rate of benign biopsies and short interval follow-up induced only by MRI in this population.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    • Patients treated with breast conserving therapy will be followed for recurrence in the ipsilateral or contralateral breast by physical examination every six month and imaging studies performed annually.

    • The imaging including mammography, physician-performed bilateral whole breast ultrasonography and a dynamic breast MRI with gadolinium-containing contrast medium will be performed according to a standard protocol. Interpretation will be conducted independently and classified according to the Breast Imaging Reporting and Data System (BI-RADS) by experienced radiologists.

    • Definitive information about the presence of malignancy will be obtained by biopsy directed by the imaging method best depicting the lesion with 14-g or 11-g needle devices or needle localized excision. The absence of breast cancer was determined by means of biopsy, the absence of positive findings on repeat imaging and clinical examination, or both at follow-up.

    • After three rounds of annual screening, the diagnostic yield of screening MRI compared to physical examination, mammography or ultrasonography will be assessed.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    754 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Screening MRI for Cancer Recurrence in Patients Treated With Breast Conserving Therapy
    Study Start Date :
    Dec 1, 2010
    Actual Primary Completion Date :
    Jan 1, 2016
    Actual Study Completion Date :
    Jan 1, 2016

    Outcome Measures

    Primary Outcome Measures

    1. Diagnostic yield of screening breast MRI [Three years after the first screening MRI]

    Secondary Outcome Measures

    1. Sensitivity, specificity, negative predictive value, and positive predictive value of screening mammography, ultrasonography, and MRI [Three years after the first screening examinations]

    Other Outcome Measures

    1. Complications of the MRI contrast agents [Three years after the first screening MRI]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 50 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Women ≥ 20 years in age;

    • Women who underwent breast-conserving surgery for invasive breast cancer, whose final margins were negative and who finished radiation therapy at least 6 months prior to this study;

    • No history of breast biopsy of the breast within 6 months prior to this study;

    • Signed study-specific informed consent prior to registration;

    • Has not had contralateral mastectomy;

    • No known metastatic disease;

    • Not pregnant or lactating;

    • No present signs or symptoms of breast cancer [no palpable mass(es), bloody or spontaneous clear nipple discharge, axillary mass, or abnormal skin changes in the breast(s) or nipple(s)].

    • No contraindications to MRI examination.

    • No prior MRI, US or mammography within the 6 months prior to the study.

    Exclusion Criteria:
    • Had a screening contrast-enhanced breast MRI within the past 24 months or diagnostic contrast-enhanced MRI on any study breasts within the past 12 months;

    • Had breast surgery and/or a core biopsy on the study breast(s) performed within the prior 6 months on the study

    • Currently receiving chemotherapy [with exception to participant with personal history of cancer, and on chemoprevention with Tamoxifen, Evista (Raloxifene), Arimidex (Anastrozole), Aromasin (Exemestane) or other aromatase inhibitor];

    • Participant with severely impaired renal function with estimated glomerular filtration rate (GFR) < 30 mL/min/1.73m2 and/or on dialysis.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Seoul National University Hospital Seoul Korea, Republic of 110-744

    Sponsors and Collaborators

    • Seoul National University Hospital

    Investigators

    • Principal Investigator: Woo Kyung Moon, M.D., Ph.D., Department of Radiology, Seoul National University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Woo Kyung Moon, Professor, Seoul National University Hospital
    ClinicalTrials.gov Identifier:
    NCT01257152
    Other Study ID Numbers:
    • Screening MR for Recurred BrCa
    First Posted:
    Dec 9, 2010
    Last Update Posted:
    Apr 20, 2016
    Last Verified:
    Apr 1, 2016

    Study Results

    No Results Posted as of Apr 20, 2016